Richard T Frederick, MD
Gastroenterology · San Francisco
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 2
Offices
2 locations · Sutter Bay Medical Foundation · 3,783 clinicians in this group
Hospitals listed: California Pacific Medical Center- Van Ness Campus · Enloe Health · Mills-Peninsula Medical Center · Oroville Hospital · Sutter Lakeside Hospital. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Frederick’s office to ask if they take your plan before you enroll.
California Medical Board record
Licence A71441 · Current
Licensed to practise in California · since 2000 · expires 2028-04-30 · New York Medical College.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
5 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- California Pacific Medical Center- Van Ness CampusSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 4 of 5 · 78% would definitely recommend itOverall rating: 3 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.224, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.325, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.373, Oct 2024 – Sep 2025
- Enloe HealthChico, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Enloe Medical CenterPatients rate it 3 of 5 · 73% would definitely recommend itOverall rating: 3 of 5 starsWorse than the national rate — Rate of emergency department (ED) visits for patients receiving outpatient chemotherapy: 6.9 (5.5 to 8.6) · 730 cases, Jan 2024 – Dec 2024Better than the national rate — Clostridium Difficile (C.Diff): 0.185, Oct 2024 – Sep 2025
- Oroville HospitalOroville, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of OroHealth CorporationPatients rate it 1 of 5 · 35% would definitely recommend itOverall rating: 1 of 5 starsWorse than the national rate — Postoperative respiratory failure rate: 16.04 (9.53 to 22.55) · 404 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.7 (11.1 to 19.4) · 136 cases, Jan 2024 – Dec 2024Better than the national rate — Clostridium Difficile (C.Diff): 0.262, Oct 2024 – Sep 2025
- Peninsula Medical CenterBurlingame, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 4 of 5 · 78% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.139, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.242, Oct 2024 – Sep 2025
- Sutter Lakeside HospitalLakeport, CACritical Access Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 4 of 5 · 76% would definitely recommend itOverall rating: 4 of 5 starsNo measure marked better or worse than the national rate
See every measure and the patient survey for California Pacific Medical Center- Van Ness Campus
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 1 better, 6 the same, 0 worse of 7 measures. Readmissions: 0 better, 8 the same, 2 worse of 10 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.224 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.325 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.373 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.14 (0.3 to 1.97) · 2,271 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.05 (0.81 to 1.28) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 192.86 (151.51 to 234.22) · 140 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.6 · 55 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 10.3 · 60 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.5 · 143 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.8 · 356 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.3 · 259 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 173 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.1 · 2,316 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.31 (0.12 to 0.49) · 6,430 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.09 to 0.47) · 7,168 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.3 (1.5 to 5.09) · 2,196 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2.47 (1.21 to 3.74) · 925 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.63 (1.37 to 3.88) · 1,954 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 10.13 (6.06 to 14.2) · 1,112 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.26 (4.67 to 9.85) · 1,084 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.67 (0.31 to 3.03) · 832 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.33 (0 to 0.85) · 5,406 cases | No different | Jul 2022 – Jun 2024 |
| MRSA BacteremiaInfections | 0.443 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.717 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.3 · 200 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.3 · 449 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 18.2 · 187 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 8.7 · 418 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 7.1 · 260 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 19.2 · 293 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (3.6 to 7.6) · 157 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.2 (7.7 to 13.5) · 157 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission for CABGUnplanned return visits | 11 · 33 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.2 · 66 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.5 (9.4 to 16.7) · 551 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.3) · 219 cases | No different | Jan 2024 – Dec 2024 |
What patients said (478 patients answered, 20% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 74% |
| Doctors "always" communicated well | 77% |
| Staff "always" explained | 59% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 75% |
| Doctors "always" treated them with courtesy and respect | 85% |
| Patients who gave a rating of "9" or "10" (high) | 75% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 70% |
| Nurses "always" listened carefully | 71% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 78% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
See every measure and the patient survey for Enloe Health
Behind the star rating — Deaths: 1 better, 7 the same, 0 worse of 8 measures. Safety: 4 better, 3 the same, 0 worse of 7 measures. Readmissions: 0 better, 9 the same, 2 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.9 (5.5 to 8.6) · 730 cases | Worse | Jan 2024 – Dec 2024 |
| Clostridium Difficile (C.Diff)Infections | 0.185 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.79 (0.96 to 2.62) · 2,849 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.99 (0.74 to 1.24) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 203.04 (164.55 to 241.54) · 191 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.8 · 117 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 9.8 · 377 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.4 · 377 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11.2 · 1,088 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 16.2 · 1,160 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.2 · 375 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.1 · 4,102 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.22 (0.05 to 0.39) · 14,875 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.17 (0 to 0.34) · 15,303 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.75 (2.11 to 5.39) · 3,517 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2.14 (0.71 to 3.56) · 1,262 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.89 (1.62 to 4.17) · 3,062 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 6.91 (1.48 to 12.34) · 1,287 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.79 (1.66 to 7.91) · 1,219 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.04 (0.64 to 3.43) · 643 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.71 (0.24 to 1.18) · 11,884 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.3 · 150 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.739 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.481 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.381 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.344 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.1 · 328 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.7 · 1,020 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -4.9 · 400 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 9.3 · 1,292 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 13.3 · 1,204 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 1,055 cases | None | Jul 2023 – Jun 2025 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.4 (10.4 to 14.7) · 730 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.3 · 102 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.5 · 90 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.6 · 304 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 14.9 (12.1 to 18.1) · 3,626 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.8 to 1.2) · 1,340 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,476 patients answered, 21% of those asked)
| Cleanliness | 2 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 57% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 77% |
| Staff "always" explained | 59% |
| Yes, staff "did" give patients this information | 85% |
| Yes, staff "did" give patients information about help after discharge | 83% |
| Doctors "always" explained things so they could understand | 70% |
| Doctors "always" listened carefully | 75% |
| Doctors "always" treated them with courtesy and respect | 85% |
| Patients who gave a rating of "9" or "10" (high) | 69% |
| Staff "always" explained new medications | 74% |
| Nurses "always" explained things so they could understand | 73% |
| Nurses "always" listened carefully | 74% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 40% |
| "YES", patients would definitely recommend the hospital | 73% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 87% |
See every measure and the patient survey for Oroville Hospital
Behind the star rating — Deaths: 3 better, 4 the same, 0 worse of 7 measures. Safety: 1 better, 6 the same, 0 worse of 7 measures. Readmissions: 0 better, 6 the same, 4 worse of 10 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Postoperative respiratory failure rateComplications and deaths | 16.04 (9.53 to 22.55) · 404 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.7 (11.1 to 19.4) · 136 cases | Worse | Jan 2024 – Dec 2024 |
| Clostridium Difficile (C.Diff)Infections | 0.262 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.07 (0.1 to 2.04) · 1,061 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.94 (0.64 to 1.23) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 161.51 (102.1 to 220.92) · 64 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 5.3 · 82 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.6 · 69 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.6 · 205 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 12.8 · 749 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 19.1 · 141 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.8 · 1,984 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.14 (0 to 0.33) · 7,583 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.31 (0.12 to 0.5) · 7,702 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.75 (0.69 to 4.81) · 1,113 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.44 (0 to 3.05) · 384 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.71 (0.23 to 3.2) · 1,061 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.47 (1.06 to 7.88) · 340 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.15 to 3.07) · 214 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.11 (0 to 0.69) · 4,910 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.5 · 161 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.497 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.451 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.1 · 39 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 26.7 · 239 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -24 · 54 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 66.7 · 254 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 60.8 · 898 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 25.5 · 851 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4.4 (2.9 to 6.6) · 136 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 7.8 · 176 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 22.8 · 96 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 14 (10.8 to 17.9) · 1,050 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.1 (0.8 to 1.5) · 285 cases | No different | Jan 2024 – Dec 2024 |
What patients said (769 patients answered, 12% of those asked)
| Cleanliness | 1 |
| Nurse communication | 1 |
| Doctor communication | 2 |
| Communication about medicines | 1 |
| Discharge information | 1 |
| Overall hospital rating | 1 |
| Quietness | 1 |
| Recommend hospital | 1 |
| Room was "always" clean | 43% |
| Nurses "always" communicated well | 64% |
| Doctors "always" communicated well | 66% |
| Staff "always" explained | 45% |
| Yes, staff "did" give patients this information | 77% |
| Yes, staff "did" give patients information about help after discharge | 74% |
| Doctors "always" explained things so they could understand | 60% |
| Doctors "always" listened carefully | 63% |
| Doctors "always" treated them with courtesy and respect | 75% |
| Patients who gave a rating of "9" or "10" (high) | 35% |
| Staff "always" explained new medications | 57% |
| Nurses "always" explained things so they could understand | 59% |
| Nurses "always" listened carefully | 60% |
| Nurses "always" treated them with courtesy and respect | 73% |
| "Always" quiet at night | 29% |
| "YES", patients would definitely recommend the hospital | 35% |
| Staff "always" explained possible side effects | 33% |
| Yes, staff "did" give patients information about possible symptoms | 80% |
See every measure and the patient survey for Peninsula Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 0 better, 10 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.139 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.242 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.21 (0.27 to 2.15) · 1,258 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.81 (0.51 to 1.1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 155.44 (112.67 to 198.21) · 90 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.5 · 32 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 82 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10 · 188 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9 · 473 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.8 · 342 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.4 · 485 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.9 · 3,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.2 (0 to 0.4) · 6,904 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.21 (0.02 to 0.4) · 7,052 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.41 (1.43 to 5.39) · 1,695 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.72 (0.17 to 3.28) · 665 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.66 to 3.56) · 1,545 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.1 (1.3 to 12.9) · 670 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.96 (2.63 to 9.29) · 653 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.15 to 3.08) · 418 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.14 (0 to 0.78) · 5,539 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.7 · 192 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.215 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.263 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.74 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.3 · 300 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19 · 702 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 1.2 · 207 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -13.6 · 531 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 24.3 · 343 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.1 · 449 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4.5 (2.8 to 7) · 85 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 9.6 (6.7 to 13.7) · 85 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.7 · 189 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11 · 45 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.6 · 117 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13 (9.7 to 17.2) · 584 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.2) · 764 cases | No different | Jan 2024 – Dec 2024 |
What patients said (523 patients answered, 27% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 76% |
| Nurses "always" communicated well | 81% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 79% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 75% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 54% |
| "YES", patients would definitely recommend the hospital | 78% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for Sutter Lakeside Hospital
Behind the star rating — Deaths: 0 better, 4 the same, 0 worse of 4 measures. Safety: 0 better, 1 the same, 0 worse of 1 measures. Readmissions: 1 better, 5 the same, 0 worse of 6 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Death rate for COPD patientsComplications and deaths | 8.7 · 46 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 10.7 · 94 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.2 · 133 cases | None | Jul 2022 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.9 · 379 cases | None | Jul 2024 – Jun 2025 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.8 · 31 cases | None | Apr 2023 – Mar 2025 |
| Clostridium Difficile (C.Diff)Infections | 1.249 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.9 · 72 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -25.4 · 92 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -37.9 · 137 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.3 · 109 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.3 · 36 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.7 · 47 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.2 (9.9 to 17.3) · 564 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.6 to 1.3) · 52 cases | No different | Jan 2024 – Dec 2024 |
What patients said (209 patients answered, 18% of those asked)
| Cleanliness | 5 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 4 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 4 |
| Recommend hospital | 4 |
| Room was "always" clean | 83% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 70% |
| Yes, staff "did" give patients this information | 90% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 72% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 85% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 82% |
| Nurses "always" explained things so they could understand | 73% |
| Nurses "always" listened carefully | 78% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 63% |
| "YES", patients would definitely recommend the hospital | 76% |
| Staff "always" explained possible side effects | 58% |
| Yes, staff "did" give patients information about possible symptoms | 91% |
Original Medicare doctor bills
$123,191
Medicare paid this office $123,191 for 461 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 65 | $30,246 | $104 |
| Long return visit (40+ min) | 145 | $28,986 | $120 |
| Long return visit (40+ min) | 148 | $27,315 | $128 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 42 | $7,355 | $153 |
| New patient visit (60+ min) | 39 | $6,669 | $171 |
See all 11 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 65 | $30,246 | $104 |
| Long return visit (40+ min) | 145 | $28,986 | $120 |
| Long return visit (40+ min) | 148 | $27,315 | $128 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 42 | $7,355 | $153 |
| New patient visit (60+ min) | 39 | $6,669 | $171 |
| Critical care, first 30-74 minutes | 15 | $4,610 | $184 |
| Return visit (30+ min) | 35 | $3,471 | $89 |
| Return visit (30+ min) | 35 | $2,828 | $76 |
| New patient visit (45+ min) | 16 | $1,839 | $115 |
| New patient visit (60+ min) | 13 | $1,808 | $139 |
| Measurement of liver stiffness | 29 | $735 | $25 |
Procedures Medicare counted
| Colonoscopy | 1-10 | None |
| Upper gastrointestinal (GI) endoscopy for acid reflux | 23 | More than 52% of doctors who do this |
Who their Medicare patients are
461 Original Medicare patients in 2024. Average age 69 · Under 65 19% · 85 and older 3% · Women 50% · Also on Medicaid 39% · Health risk score 2.36. Sicker patients than 9 in 10 peers; the typical gastroenterology clinician is at 1.42.
Conditions among them: High blood pressure 74% · Diabetes 39% · Chronic kidney disease 36% · Depression 25% · Coronary heart disease 23% · Heart failure 19% · COPD 17% · Atrial fibrillation 17% · Cancer 13% · Dementia 6% · Stroke 6%.
The office billed $546,964, Medicare allowed $164,391 and paid $123,191; for 1,066 services of 22 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 461 | 1,066 | 69 | 2.36 | $546,964 | $123,191 |
| 2023 | 450 | 1,001 | 68 | 2.43 | $504,427 | $116,359 |
| 2022 | 467 | 1,030 | 68 | 2.26 | $510,321 | $119,442 |
| 2021 | 461 | 1,093 | 68 | 2.41 | $513,673 | $126,731 |
| 2020 | 479 | 1,175 | 67 | 2.59 | $575,020 | $119,140 |
| 2019 | 495 | 1,091 | 67 | 2.62 | $551,856 | $104,104 |
| 2018 | 460 | 1,030 | 66 | 2.60 | $529,075 | $97,908 |
| 2017 | 468 | 1,038 | 66 | 2.38 | $523,821 | $96,379 |
| 2016 | 487 | 1,100 | 65 | 2.49 | $527,207 | $105,412 |
| 2015 | 454 | 970 | 64 | 2.32 | $520,523 | $97,204 |
| 2014 | 454 | 1,065 | 64 | 2.26 | $600,585 | $121,724 |
| 2013 | 461 | 1,077 | 63 | 2.74 | $558,048 | $115,000 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 11 services
| Long return visit (40+ min) | 147 | $26,155 | $135 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 63 | $25,690 | $108 |
| Long return visit (40+ min) | 120 | $21,848 | $118 |
| Critical care, first 30-74 minutes | 13 | $10,610 | $189 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 39 | $6,766 | $157 |
| New patient visit (60+ min) | 37 | $5,634 | $152 |
| Return visit (30+ min) | 51 | $4,690 | $84 |
| Return visit (30+ min) | 41 | $3,272 | $70 |
| New patient visit (45+ min) | 15 | $1,759 | $117 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 14 | $1,651 | $72 |
| Measurement of liver stiffness | 26 | $520 | $20 |
2022: 12 services
| Long return visit (40+ min) | 131 | $28,944 | $123 |
| Long return visit (40+ min) | 145 | $26,928 | $131 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 59 | $17,136 | $92 |
| Critical care, first 30-74 minutes | 22 | $11,945 | $187 |
| New patient visit (60+ min) | 47 | $7,624 | $162 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 35 | $6,555 | $172 |
| Return visit (30+ min) | 48 | $4,283 | $75 |
| Return visit (30+ min) | 47 | $4,252 | $89 |
| New patient visit (60+ min) | 13 | $1,986 | $153 |
| New patient visit (45+ min) | 16 | $1,517 | $95 |
| Short return visit (20+ min) | 12 | $726 | $60 |
| Measurement of liver stiffness | 26 | $653 | $24 |
2021: 14 services
| Long return visit (40+ min) | 167 | $33,463 | $134 |
| Long return visit (40+ min) | 134 | $27,033 | $120 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 66 | $21,345 | $93 |
| Critical care, first 30-74 minutes | 16 | $9,770 | $195 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 37 | $6,878 | $181 |
| New patient visit (60+ min) | 39 | $6,289 | $161 |
| Return visit (30+ min) | 45 | $5,045 | $93 |
| Return visit (30+ min) | 46 | $4,166 | $80 |
| New patient visit (60+ min) | 12 | $2,060 | $172 |
| New patient visit (45+ min) | 15 | $1,648 | $110 |
| Telephone medical discussion with physician, 21-30 minutes | 18 | $1,465 | $81 |
| Telephone medical discussion with physician, 21-30 minutes | 11 | $834 | $76 |
| Measurement of liver stiffness | 15 | $154 | $10 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 14 | $72 | $5 |
2020: 15 services
| Long return visit (40+ min) | 152 | $24,418 | $111 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 67 | $24,251 | $94 |
| Long return visit (40+ min) | 118 | $17,146 | $92 |
| Critical care, first 30-74 minutes | 12 | $12,129 | $199 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 42 | $7,672 | $183 |
| New patient visit (60+ min) | 39 | $5,806 | $149 |
| Telephone medical discussion with physician, 21-30 minutes | 53 | $5,634 | $89 |
| Return visit (30+ min) | 56 | $4,914 | $81 |
| Return visit (30+ min) | 46 | $2,856 | $57 |
| New patient visit (60+ min) | 20 | $2,511 | $126 |
| Telephone medical discussion with physician, 21-30 minutes | 20 | $1,601 | $73 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 13 | $1,513 | $66 |
| New patient visit (45+ min) | 11 | $1,048 | $95 |
| Measurement of liver stiffness | 26 | $303 | $11 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 16 | $84 | $5 |
2019: 17 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 78 | $25,958 | $94 |
| Long return visit (40+ min) | 127 | $18,406 | $105 |
| Long return visit (40+ min) | 77 | $10,171 | $92 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 47 | $9,020 | $180 |
| Return visit (30+ min) | 73 | $5,236 | $61 |
| Return visit (30+ min) | 58 | $4,714 | $77 |
| New patient visit (60+ min) | 30 | $4,323 | $144 |
| New patient visit (60+ min) | 24 | $3,398 | $142 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 23 | $2,230 | $66 |
| New patient visit (45+ min) | 17 | $2,070 | $122 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 19 | $1,885 | $99 |
| New patient visit (45+ min) | 15 | $1,505 | $100 |
| Short return visit (20+ min) | 16 | $784 | $39 |
| Short return visit (20+ min) | 11 | $678 | $57 |
| Measurement of liver stiffness | 42 | $561 | $12 |
| Measurement of liver stiffness | 19 | $531 | $28 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 19 | $97 | $5 |
2018: 14 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 74 | $23,007 | $90 |
| Long return visit (40+ min) | 155 | $22,082 | $105 |
| Critical care, first 30-74 minutes | 22 | $10,170 | $188 |
| Long return visit (40+ min) | 76 | $9,700 | $90 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 40 | $7,159 | $175 |
| Return visit (30+ min) | 55 | $4,545 | $73 |
| Return visit (30+ min) | 60 | $3,918 | $58 |
| New patient visit (60+ min) | 20 | $2,799 | $140 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 27 | $2,399 | $62 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 16 | $1,533 | $96 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 13 | $1,417 | $109 |
| Measurement of liver stiffness | 32 | $444 | $12 |
| Measurement of liver stiffness | 12 | $321 | $27 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 23 | $116 | $5 |
2017: 17 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 62 | $18,796 | $90 |
| Long return visit (40+ min) | 133 | $18,560 | $105 |
| Long return visit (40+ min) | 87 | $12,258 | $88 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 39 | $7,066 | $172 |
| Critical care, first 30-74 minutes | 12 | $6,457 | $190 |
| Return visit (30+ min) | 72 | $6,027 | $75 |
| Return visit (30+ min) | 71 | $5,031 | $61 |
| New patient visit (60+ min) | 27 | $4,255 | $158 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 23 | $2,430 | $106 |
| New patient visit (60+ min) | 16 | $2,329 | $146 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 20 | $2,131 | $63 |
| New patient visit (45+ min) | 14 | $1,623 | $116 |
| New patient visit (45+ min) | 12 | $1,226 | $102 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 12 | $1,090 | $91 |
| Measurement of liver stiffness | 38 | $485 | $12 |
| Measurement of liver stiffness | 14 | $315 | $22 |
| Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monito | 27 | $149 | $5 |
2016: 12 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 73 | $27,758 | $93 |
| Long return visit (40+ min) | 168 | $24,315 | $106 |
| Long return visit (40+ min) | 86 | $12,823 | $91 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 36 | $6,886 | $181 |
| Return visit (30+ min) | 65 | $5,148 | $63 |
| Return visit (30+ min) | 54 | $4,889 | $79 |
| New patient visit (60+ min) | 31 | $4,803 | $155 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 24 | $2,394 | $65 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 17 | $2,014 | $118 |
| New patient visit (60+ min) | 14 | $1,936 | $138 |
| Measurement of liver stiffness | 22 | $581 | $26 |
| Measurement of liver stiffness | 45 | $544 | $12 |
2015: 11 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 74 | $21,334 | $93 |
| Long return visit (40+ min) | 158 | $20,289 | $103 |
| Long return visit (40+ min) | 76 | $9,902 | $93 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 41 | $7,752 | $180 |
| New patient visit (60+ min) | 37 | $5,962 | $161 |
| Return visit (30+ min) | 57 | $4,046 | $66 |
| Return visit (30+ min) | 61 | $3,920 | $63 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 32 | $3,485 | $65 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 26 | $3,001 | $115 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 17 | $1,996 | $111 |
| Measurement of liver stiffness | 30 | $390 | $13 |
2014: 12 services
| Long return visit (40+ min) | 192 | $41,559 | $116 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 67 | $17,543 | $93 |
| Return visit (30+ min) | 109 | $11,223 | $83 |
| Critical care, first 30-74 minutes | 11 | $9,215 | $196 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 43 | $8,130 | $181 |
| New patient visit (60+ min) | 43 | $7,378 | $172 |
| Long return visit (40+ min) | 36 | $4,751 | $95 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 33 | $3,788 | $115 |
| New patient visit (45+ min) | 30 | $3,681 | $123 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 29 | $3,345 | $64 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 20 | $2,567 | $122 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 12 | $1,243 | $89 |
2013: 10 services
| Long return visit (40+ min) | 249 | $41,796 | $111 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 76 | $24,151 | $90 |
| Return visit (30+ min) | 88 | $8,912 | $87 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 46 | $8,458 | $176 |
| New patient visit (60+ min) | 49 | $7,930 | $162 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 45 | $5,375 | $63 |
| Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 20 | $2,543 | $121 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 19 | $2,264 | $119 |
| New patient visit (45+ min) | 14 | $1,950 | $139 |
| Long return visit (40+ min) | 11 | $1,084 | $83 |
Medicaid work
$22,430 in 2024
Medicaid paid $22,430 for 364 billed services this clinician did in 2024, up to 32 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Long return visit (40+ min) | 232 | $14,545 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 132 | $7,885 |
| 2024 | 364 | 2 | 32 | $22,430 |
| 2023 | 414 | 2 | 32 | $28,285 |
| 2022 | 334 | 2 | 29 | $20,033 |
| 2021 | 382 | 2 | 37 | $26,781 |
| 2020 | 327 | 2 | 35 | $16,926 |
| 2019 | 135 | 2 | 25 | $8,481 |
| 2018 | 175 | 2 | 18 | $10,883 |
See the largest Medicaid services in earlier years
2023
| Long return visit (40+ min) | 303 | $21,200 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 111 | $7,086 |
2022
| Long return visit (40+ min) | 236 | $15,042 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 98 | $4,991 |
2021
| Long return visit (40+ min) | 300 | $22,785 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 82 | $3,996 |
2020
| Long return visit (40+ min) | 284 | $15,355 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 43 | $1,571 |
2019
| Long return visit (40+ min) | 100 | $6,693 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 35 | $1,788 |
2018
| Long return visit (40+ min) | 95 | $6,816 |
| SBSQ HOSPITAL IP/OBS CARE HIGH MDM 50 MINUTES | 80 | $4,067 |
Drugs they prescribed that Part D paid
$1,729,606
Pharmacies billed $1,729,606 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
1,409 generic and fewer than 11 brand-name prescriptions · $1,729,606 in drug cost · 205 antibiotic prescriptions to 34 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Epclusa | 18 | $422,141 | $23,452 |
| Xifaxan | 122 | $402,504 | $3,299 |
| Vemlidy | 151 | $238,599 | $1,580 |
| Rezdiffra | 24 | $90,651 | $3,777 |
| Entecavir | 120 | $47,114 | $393 |
See all 30 drugs
| Epclusa | 18 | $422,141 | $23,452 |
| Xifaxan | 122 | $402,504 | $3,299 |
| Vemlidy | 151 | $238,599 | $1,580 |
| Rezdiffra | 24 | $90,651 | $3,777 |
| Entecavir | 120 | $47,114 | $393 |
| Ursodiol | 241 | $40,011 | $166 |
| Tacrolimus | 248 | $29,616 | $119 |
| Mycophenolate Mofetil | 62 | $11,912 | $192 |
| Eliquis | 17 | $10,198 | $600 |
| Prograf | 19 | $10,163 | $535 |
| Mycophenolic Acid | 27 | $5,047 | $187 |
| Lactulose | 72 | $4,029 | $56 |
| Valganciclovir | 22 | $3,602 | $164 |
| Budesonide Ec | 21 | $3,425 | $163 |
| Budesonide Dr | 15 | $2,255 | $150 |
| Pantoprazole | 65 | $810 | $12 |
| Spironolactone | 54 | $759 | $14 |
| Eplerenone | 27 | $755 | $28 |
| Constulose | 15 | $705 | $47 |
| Prednisone | 65 | $684 | $11 |
| Furosemide | 69 | $553 | $8 |
| Fenofibrate | 16 | $534 | $33 |
| Azathioprine | 13 | $417 | $32 |
| Fluconazole | 20 | $346 | $17 |
| Sulfamethoxazole-Trimethoprim | 52 | $247 | $5 |
| Omeprazole | 22 | $198 | $9 |
| Amoxicillin-Clavulanate Potass | 11 | $102 | $9 |
| Amlodipine Besylate | 13 | $49 | $4 |
| Metoprolol | 17 | $40 | $2 |
| Carvedilol | 20 | $23 | $1 |
Year by year
| 2024 | 1,898 | 242 | None | None | $1,729,606 |
| 2023 | 1,605 | 231 | None | None | $1,334,969 |
| 2022 | 1,765 | 223 | None | None | $2,115,235 |
| 2021 | 1,618 | 210 | None | None | $1,387,425 |
| 2020 | 1,767 | 200 | None | None | $2,169,024 |
| 2019 | 1,528 | 201 | None | 33% | $1,453,573 |
| 2018 | 1,476 | 188 | 1% (12) | 27% | $1,307,338 |
| 2017 | 1,498 | 185 | 1% (19) | 31% | $1,988,973 |
| 2016 | 1,422 | 178 | 1% (18) | None | $2,426,921 |
| 2015 | 1,904 | 227 | 1% (20) | None | $8,385,128 |
| 2014 | 1,834 | 214 | 1% (24) | 38% | $5,771,629 |
| 2013 | 1,679 | 208 | 2% (32) | 38% | $736,265 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 23 drugs
| Xifaxan | 109 | $394,140 | $3,616 |
| Vemlidy | 136 | $247,240 | $1,818 |
| Entecavir | 109 | $51,471 | $472 |
| Ursodiol | 225 | $48,287 | $215 |
| Tacrolimus | 224 | $47,044 | $210 |
| Mycophenolate Mofetil | 58 | $15,176 | $262 |
| Budesonide Dr | 35 | $12,260 | $350 |
| Prograf | 11 | $10,611 | $965 |
| Lactulose | 90 | $6,409 | $71 |
| Budesonide Ec | 13 | $3,602 | $277 |
| Spironolactone | 60 | $1,305 | $22 |
| Constulose | 14 | $1,192 | $85 |
| Prednisone | 60 | $1,032 | $17 |
| Bumetanide | 12 | $966 | $80 |
| Eplerenone | 14 | $937 | $67 |
| Azathioprine | 27 | $820 | $30 |
| Furosemide | 63 | $628 | $10 |
| Pantoprazole | 40 | $578 | $14 |
| Metoprolol | 18 | $299 | $17 |
| Omeprazole | 15 | $178 | $12 |
| Sulfasalazine | 11 | $173 | $16 |
| Sulfamethoxazole-Trimethoprim | 13 | $51 | $4 |
| Carvedilol | 14 | $44 | $3 |
2022: 26 drugs
| Epclusa | 35 | $932,265 | $26,636 |
| Xifaxan | 138 | $458,211 | $3,320 |
| Vemlidy | 141 | $209,374 | $1,485 |
| Ocaliva | 18 | $170,825 | $9,490 |
| Ursodiol | 247 | $67,586 | $274 |
| Tacrolimus | 208 | $33,997 | $163 |
| Entecavir | 86 | $23,766 | $276 |
| Valganciclovir | 11 | $18,365 | $1,670 |
| Lactulose | 95 | $7,308 | $77 |
| Mycophenolate Mofetil | 66 | $7,047 | $107 |
| Budesonide Ec | 27 | $6,783 | $251 |
| Budesonide Dr | 32 | $6,183 | $193 |
| Mycophenolic Acid | 14 | $5,748 | $411 |
| Spironolactone | 80 | $1,410 | $18 |
| Constulose | 17 | $1,192 | $70 |
| Azathioprine | 17 | $1,188 | $70 |
| Eplerenone | 14 | $1,157 | $83 |
| Prednisone | 63 | $800 | $13 |
| Pantoprazole | 64 | $754 | $12 |
| Cyclosporine Modified | 17 | $730 | $43 |
| Furosemide | 102 | $561 | $6 |
| Midodrine | 11 | $521 | $47 |
| Fluconazole | 12 | $446 | $37 |
| Sulfasalazine | 11 | $231 | $21 |
| Sulfamethoxazole-Trimethoprim | 22 | $97 | $4 |
| Omeprazole | 11 | $72 | $7 |
2021: 22 drugs
| Xifaxan | 174 | $498,853 | $2,867 |
| Epclusa | 14 | $366,655 | $26,190 |
| Vemlidy | 99 | $147,813 | $1,493 |
| Ursodiol | 217 | $57,834 | $267 |
| Tacrolimus | 181 | $35,020 | $193 |
| Entecavir | 80 | $19,237 | $240 |
| Mycophenolic Acid | 12 | $7,945 | $662 |
| Valganciclovir | 20 | $7,639 | $382 |
| Mycophenolate Mofetil | 47 | $6,956 | $148 |
| Lactulose | 105 | $5,952 | $57 |
| Budesonide Ec | 22 | $3,459 | $157 |
| Budesonide Dr | 20 | $2,704 | $135 |
| Spironolactone | 92 | $2,177 | $24 |
| Azathioprine | 31 | $1,467 | $47 |
| Cyclosporine Modified | 17 | $1,238 | $73 |
| Pantoprazole | 81 | $745 | $9 |
| Constulose | 15 | $646 | $43 |
| Prednisone | 43 | $482 | $11 |
| Fluconazole | 11 | $472 | $43 |
| Furosemide | 67 | $465 | $7 |
| Omeprazole | 23 | $248 | $11 |
| Sulfamethoxazole-Trimethoprim | 14 | $64 | $5 |
2020: 25 drugs
| Epclusa | 34 | $874,389 | $25,717 |
| Xifaxan | 210 | $566,120 | $2,696 |
| Vemlidy | 77 | $127,772 | $1,659 |
| Ursodiol | 224 | $81,003 | $362 |
| Truvada | 12 | $38,160 | $3,180 |
| Tacrolimus | 174 | $34,941 | $201 |
| Entecavir | 78 | $22,145 | $284 |
| Valganciclovir | 30 | $15,221 | $507 |
| Budesonide Ec | 47 | $13,804 | $294 |
| Mycophenolic Acid | 14 | $8,600 | $614 |
| Mycophenolate Mofetil | 73 | $8,123 | $111 |
| Lactulose | 93 | $5,889 | $63 |
| Spironolactone | 109 | $2,117 | $19 |
| Cyclosporine Modified | 22 | $1,993 | $91 |
| Azathioprine | 28 | $1,447 | $52 |
| Ribavirin | 15 | $1,037 | $69 |
| Constulose | 28 | $958 | $34 |
| Pantoprazole | 78 | $724 | $9 |
| Fluconazole | 14 | $667 | $48 |
| Furosemide | 89 | $571 | $6 |
| Prednisone | 32 | $478 | $15 |
| Levothyroxine | 21 | $259 | $12 |
| Omeprazole | 19 | $241 | $13 |
| Sulfamethoxazole-Trimethoprim | 20 | $90 | $5 |
| Metoprolol | 14 | $85 | $6 |
2019: 27 drugs
| Xifaxan | 158 | $382,967 | $2,424 |
| Mavyret | 12 | $158,804 | $13,234 |
| Vemlidy | 98 | $134,011 | $1,367 |
| Ursodiol | 186 | $79,654 | $428 |
| Ocaliva | 11 | $75,415 | $6,856 |
| Entecavir | 86 | $34,764 | $404 |
| Truvada | 17 | $31,159 | $1,833 |
| Tacrolimus | 208 | $18,219 | $88 |
| Budesonide Ec | 57 | $11,138 | $195 |
| Mycophenolate Mofetil | 54 | $9,528 | $176 |
| Mycophenolic Acid | 22 | $4,236 | $193 |
| Levemir | 11 | $3,421 | $311 |
| Tenofovir Disoproxil | 17 | $3,261 | $192 |
| Lactulose | 64 | $2,903 | $45 |
| Azathioprine | 38 | $2,170 | $57 |
| Spironolactone | 66 | $1,531 | $23 |
| Eplerenone | 12 | $1,467 | $122 |
| Cyclosporine Modified | 21 | $1,350 | $64 |
| Furosemide | 60 | $551 | $9 |
| Pantoprazole | 42 | $523 | $12 |
| Metolazone | 13 | $509 | $39 |
| Constulose | 20 | $378 | $19 |
| Levothyroxine | 24 | $312 | $13 |
| Prednisone | 26 | $197 | $8 |
| Ciprofloxacin | 17 | $181 | $11 |
| Omeprazole | 12 | $129 | $11 |
| Metoprolol | 11 | $95 | $9 |
2018: 24 drugs
| Xifaxan | 143 | $314,119 | $2,197 |
| Ursodiol | 147 | $87,149 | $593 |
| Entecavir | 110 | $74,488 | $677 |
| Vemlidy | 49 | $65,306 | $1,333 |
| Truvada | 12 | $21,376 | $1,781 |
| Tenofovir Disoproxil | 39 | $17,888 | $459 |
| Tacrolimus | 165 | $17,458 | $106 |
| Viread | 12 | $14,416 | $1,201 |
| Budesonide Ec | 55 | $13,645 | $248 |
| Mycophenolate Mofetil | 46 | $6,207 | $135 |
| Mycophenolic Acid | 21 | $5,130 | $244 |
| Eplerenone | 13 | $2,484 | $191 |
| Lactulose | 73 | $2,421 | $33 |
| Azathioprine | 37 | $1,935 | $52 |
| Spironolactone | 103 | $1,246 | $12 |
| Furosemide | 102 | $508 | $5 |
| Prednisone | 29 | $406 | $14 |
| Pantoprazole | 33 | $378 | $11 |
| Fludrocortisone Acetate | 13 | $234 | $18 |
| Amlodipine Besylate | 21 | $182 | $9 |
| Levothyroxine | 13 | $166 | $13 |
| Ciprofloxacin | 14 | $75 | $5 |
| Metoprolol | 19 | $71 | $4 |
| Sulfamethoxazole-Trimethoprim | 17 | $61 | $4 |
2017: 26 drugs
| Harvoni | 13 | $416,144 | $32,011 |
| Epclusa | 11 | $266,863 | $24,260 |
| Xifaxan | 108 | $248,112 | $2,297 |
| Entecavir | 114 | $96,633 | $848 |
| Viread | 66 | $72,803 | $1,103 |
| Ursodiol | 121 | $53,081 | $439 |
| Budesonide Ec | 56 | $36,223 | $647 |
| Tacrolimus | 165 | $16,311 | $99 |
| Mycophenolic Acid | 27 | $12,718 | $471 |
| Mycophenolate Mofetil | 53 | $11,405 | $215 |
| Lactulose | 48 | $2,316 | $48 |
| Amiloride | 14 | $2,136 | $153 |
| Azathioprine | 45 | $1,871 | $42 |
| Spironolactone | 83 | $993 | $12 |
| Nystatin | 16 | $528 | $33 |
| Prednisone | 42 | $456 | $11 |
| Furosemide | 84 | $353 | $4 |
| Pantoprazole | 34 | $349 | $10 |
| Fludrocortisone Acetate | 16 | $274 | $17 |
| Omeprazole | 24 | $242 | $10 |
| Amlodipine Besylate | 22 | $209 | $10 |
| Ciprofloxacin | 21 | $193 | $9 |
| Ondansetron | 13 | $92 | $7 |
| Hydroxyzine | 11 | $65 | $6 |
| Sulfamethoxazole-Trimethoprim | 22 | $42 | $2 |
| Metoprolol | 14 | $42 | $3 |
2016: 29 drugs
| Harvoni | 29 | $912,426 | $31,463 |
| Sovaldi | 13 | $351,000 | $27,000 |
| Epclusa | 14 | $333,546 | $23,825 |
| Xifaxan | 87 | $172,671 | $1,985 |
| Entecavir | 107 | $76,471 | $715 |
| Viread | 61 | $58,746 | $963 |
| Ursodiol | 105 | $56,965 | $543 |
| Budesonide Ec | 54 | $26,168 | $485 |
| Valganciclovir | 15 | $22,983 | $1,532 |
| Truvada | 12 | $19,294 | $1,608 |
| Mycophenolic Acid | 25 | $13,128 | $525 |
| Cellcept | 12 | $11,229 | $936 |
| Tacrolimus | 137 | $10,318 | $75 |
| Mycophenolate Mofetil | 75 | $8,479 | $113 |
| Ribavirin | 27 | $3,952 | $146 |
| Amiloride | 27 | $2,876 | $107 |
| Azathioprine | 43 | $1,653 | $38 |
| Lactulose | 42 | $1,636 | $39 |
| Nadolol | 24 | $1,517 | $63 |
| Spironolactone | 61 | $995 | $16 |
| Prednisone | 53 | $919 | $17 |
| Pantoprazole | 45 | $348 | $8 |
| Furosemide | 58 | $328 | $6 |
| Omeprazole | 24 | $261 | $11 |
| Levothyroxine | 13 | $132 | $10 |
| Amlodipine Besylate | 32 | $100 | $3 |
| Metoprolol | 12 | $64 | $5 |
| Tramadol | 12 | $60 | $5 |
| Sulfamethoxazole-Trimethoprim | 13 | $49 | $4 |
2015: 34 drugs
| Harvoni | 216 | $6,794,508 | $31,456 |
| Sovaldi | 30 | $801,042 | $26,701 |
| Xifaxan | 86 | $138,275 | $1,608 |
| Viread | 97 | $94,437 | $974 |
| Entecavir | 95 | $91,690 | $965 |
| Ursodiol | 81 | $52,003 | $642 |
| Ribavirin | 130 | $25,269 | $194 |
| Tacrolimus | 133 | $21,159 | $159 |
| Budesonide Ec | 46 | $18,224 | $396 |
| Sirolimus | 13 | $9,852 | $758 |
| Prograf | 13 | $6,440 | $495 |
| Truvada | 14 | $5,532 | $395 |
| Mycophenolate Mofetil | 52 | $5,018 | $96 |
| Cyclosporine Modified | 16 | $3,427 | $214 |
| Lactulose | 34 | $3,122 | $92 |
| Nadolol | 27 | $2,512 | $93 |
| Spironolactone | 71 | $1,307 | $18 |
| Amiloride | 11 | $1,020 | $93 |
| Pantoprazole | 83 | $729 | $9 |
| Prednisone | 28 | $623 | $22 |
| Omeprazole | 54 | $616 | $11 |
| Nystatin | 12 | $430 | $36 |
| Furosemide | 67 | $404 | $6 |
| Azathioprine | 13 | $357 | $27 |
| Amlodipine Besylate | 61 | $317 | $5 |
| Zolpidem | 19 | $311 | $16 |
| Metoprolol | 46 | $288 | $6 |
| Fludrocortisone Acetate | 11 | $215 | $20 |
| Levothyroxine | 13 | $158 | $12 |
| Metronidazole | 16 | $130 | $8 |
| Sulfamethoxazole-Trimethoprim | 19 | $118 | $6 |
| Ciprofloxacin | 19 | $110 | $6 |
| Hydrocodone-Acetaminophen | 14 | $84 | $6 |
| Trazodone | 11 | $83 | $8 |
2014: 38 drugs
| Sovaldi | 95 | $2,702,594 | $28,448 |
| Harvoni | 43 | $1,374,633 | $31,968 |
| Olysio | 45 | $1,018,420 | $22,632 |
| Xifaxan | 122 | $176,151 | $1,444 |
| Viread | 94 | $92,693 | $986 |
| Valcyte | 23 | $90,260 | $3,924 |
| Baraclude | 60 | $71,521 | $1,192 |
| Entecavir | 31 | $29,678 | $957 |
| Ursodiol | 63 | $20,007 | $318 |
| Tacrolimus | 88 | $17,095 | $194 |
| Budesonide Ec | 15 | $9,377 | $625 |
| Ribavirin | 52 | $9,363 | $180 |
| Kristalose | 13 | $9,161 | $705 |
| Rapamune | 13 | $6,779 | $521 |
| Dyrenium | 13 | $5,864 | $451 |
| Mycophenolate Mofetil | 53 | $5,717 | $108 |
| Nexium | 12 | $4,629 | $386 |
| Nadolol | 45 | $4,288 | $95 |
| Humalog | 11 | $3,974 | $361 |
| Cyclosporine | 24 | $3,791 | $158 |
| Spironolactone | 85 | $2,382 | $28 |
| Lactulose | 38 | $2,321 | $61 |
| Prograf | 12 | $2,142 | $179 |
| Generlac | 17 | $1,438 | $85 |
| Pantoprazole | 84 | $1,391 | $17 |
| Prednisone | 38 | $880 | $23 |
| Omeprazole | 50 | $782 | $16 |
| Amlodipine Besylate | 59 | $476 | $8 |
| Furosemide | 78 | $445 | $6 |
| Metoprolol | 67 | $390 | $6 |
| Fludrocortisone Acetate | 17 | $268 | $16 |
| Olanzapine | 11 | $267 | $24 |
| Azathioprine | 11 | $267 | $24 |
| Levothyroxine | 15 | $202 | $13 |
| Propranolol | 23 | $180 | $8 |
| Sulfamethoxazole-Trimethoprim | 41 | $177 | $4 |
| Trazodone | 18 | $150 | $8 |
| Tramadol | 12 | $59 | $5 |
2013: 36 drugs
| Xifaxan | 112 | $159,031 | $1,420 |
| Viread | 112 | $107,932 | $964 |
| Valcyte | 29 | $104,524 | $3,604 |
| Baraclude | 79 | $80,465 | $1,019 |
| Pegasys | 20 | $57,638 | $2,882 |
| Tacrolimus | 72 | $19,844 | $276 |
| Neupogen | 13 | $18,784 | $1,445 |
| Myfortic | 22 | $11,664 | $530 |
| Budesonide Ec | 15 | $9,239 | $616 |
| Prograf | 32 | $9,073 | $284 |
| Ursodiol | 67 | $8,495 | $127 |
| Mycophenolate Mofetil | 77 | $8,429 | $109 |
| Rapamune | 22 | $8,317 | $378 |
| Kristalose | 16 | $3,559 | $222 |
| Nadolol | 52 | $3,284 | $63 |
| Spironolactone | 68 | $2,992 | $44 |
| Protonix | 12 | $2,830 | $236 |
| Cyclosporine | 16 | $2,574 | $161 |
| Gengraf | 15 | $1,898 | $127 |
| Lactulose | 34 | $1,854 | $55 |
| Amiloride | 15 | $1,326 | $88 |
| Pantoprazole | 65 | $958 | $15 |
| Omeprazole | 50 | $903 | $18 |
| Prednisone | 47 | $531 | $11 |
| Amlodipine Besylate | 45 | $443 | $10 |
| Furosemide | 64 | $411 | $6 |
| Fludrocortisone Acetate | 29 | $388 | $13 |
| Olanzapine | 13 | $319 | $25 |
| Azathioprine | 21 | $259 | $12 |
| Metoprolol | 48 | $215 | $4 |
| Hydrocodone-Acetaminophen | 14 | $208 | $15 |
| Propranolol | 19 | $181 | $10 |
| Ciprofloxacin | 17 | $144 | $8 |
| Trazodone | 17 | $138 | $8 |
| Sulfamethoxazole-Trimethoprim | 32 | $116 | $4 |
| Levothyroxine | 11 | $103 | $9 |
Money from drug and device companies
$45,689 in 2025
| 2025 | 7 | 35 | $42,547 | $45,689 |
| 2024 | 3 | 15 | $18,548 | $21,359 |
| 2023 | 2 | 2 | $5,893 | $5,893 |
| 2022 | 2 | 4 | $5,005 | $5,211 |
| 2021 | 1 | 7 | $20,770 | $20,770 |
| 2020 | 2 | 10 | $31,458 | $32,103 |
| 2019 | 4 | 11 | $10,920 | $11,420 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Madrigal Pharmaceuticals | Rezdiffra | $41,813 | 27 payments
|
| Mallinckrodt Hospital Products | Terlivaz | $2,995 | 3 payments
|
| Cipla USA | None | $450 | 1 payment
|
| Gilead Sciences | Livdelzi | $140 | 1 payment
|
| Salix Pharmaceuticals a division of Bausch Health US | Xifaxan | $119 | 1 payment
|
| Cook Medical | Echotip Insight | $112 | 1 payment
|
See all 35 published payments
| Salix Pharmaceuticals a division of Bausch Health US | Meals · 2025-12-03 | Xifaxan | $119 |
| Mallinckrodt Hospital Products | Meals · 2025-11-08 | Terlivaz | $125 |
| Mallinckrodt Hospital Products | Consulting · 2025-10-29 | Terlivaz | $2,790 |
| Madrigal Pharmaceuticals | Meals · 2025-10-29 | Rezdiffra | $139 |
| Madrigal Pharmaceuticals | Paid to speak or teach · 2025-10-29 | Rezdiffra | $3,878 |
| Madrigal Pharmaceuticals | Travel · 2025-10-29 | Rezdiffra | $141 |
| Madrigal Pharmaceuticals | Meals · 2025-09-11 | Rezdiffra | $95 |
| Madrigal Pharmaceuticals | Paid to speak or teach · 2025-09-11 | Rezdiffra | $3,878 |
| Madrigal Pharmaceuticals | Travel · 2025-09-11 | Rezdiffra | $131 |
| Madrigal Pharmaceuticals | Meals · 2025-08-18 | Rezdiffra | $142 |
| Madrigal Pharmaceuticals | Paid to speak or teach · 2025-08-18 | Rezdiffra | $4,935 |
| Madrigal Pharmaceuticals | Travel · 2025-08-18 | Rezdiffra | $17 |
| Madrigal Pharmaceuticals | Meals · 2025-08-12 | Rezdiffra | $73 |
| Madrigal Pharmaceuticals | Paid to speak or teach · 2025-08-12 | Rezdiffra | $3,878 |
| Madrigal Pharmaceuticals | Travel · 2025-08-12 | Rezdiffra | $122 |
| Madrigal Pharmaceuticals | Paid to speak or teach · 2025-07-31 | Rezdiffra | $1,234 |
| Madrigal Pharmaceuticals | Meals · 2025-07-30 | Rezdiffra | $104 |
| Madrigal Pharmaceuticals | Paid to speak or teach · 2025-07-30 | Rezdiffra | $3,878 |
| Madrigal Pharmaceuticals | Travel · 2025-07-30 | Rezdiffra | $185 |
| Cook Medical | Meals · 2025-07-17 | Echotip Insight | $112 |
| Madrigal Pharmaceuticals | Paid to speak or teach · 2025-06-26 | Rezdiffra | $3,878 |
| Madrigal Pharmaceuticals | Meals · 2025-06-26 | Rezdiffra | $137 |
| Madrigal Pharmaceuticals | Travel · 2025-06-26 | Rezdiffra | $116 |
| Mallinckrodt Hospital Products | Meals · 2025-05-07 | Terlivaz | $80 |
| Gilead Sciences | Meals · 2025-05-05 | Livdelzi | $140 |
| Madrigal Pharmaceuticals | Paid to speak or teach · 2025-04-14 | Rezdiffra | $4,935 |
| Madrigal Pharmaceuticals | Meals · 2025-04-14 | Rezdiffra | $55 |
| Ipsen Biopharmaceuticals | Meals · 2025-03-18 | Iqirvo | $62 |
| Madrigal Pharmaceuticals | Paid to speak or teach · 2025-03-10 | Rezdiffra | $3,878 |
| Madrigal Pharmaceuticals | Meals · 2025-02-11 | Rezdiffra | $108 |
| Madrigal Pharmaceuticals | Paid to speak or teach · 2025-02-11 | Rezdiffra | $4,935 |
| Madrigal Pharmaceuticals | Travel · 2025-02-11 | Rezdiffra | $810 |
| Cipla USA | Consulting · 2025-02-10 | None | $450 |
| Madrigal Pharmaceuticals | Meals · 2025-01-29 | Rezdiffra | $33 |
| Madrigal Pharmaceuticals | Travel · 2025-01-29 | Rezdiffra | $99 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $21,359
| Madrigal Pharmaceuticals | Rezdiffra | $15,032 | 11 payments
|
| Mallinckrodt Hospital Products | Terlivaz | $3,787 | 2 payments
|
| Ipsen Biopharmaceuticals | Iqirvo | $2,540 | 2 payments
|
2023: $5,893
| Mallinckrodt Hospital Products | Terlivaz | $5,580 | 1 payment
|
| TerSera Therapeutics | None | $313 | 1 payment
|
2022: $5,211
| Mallinckrodt Hospital Products | Terlivaz | $5,153 | 2 payments
|
| AstraZeneca UK | None | $58 | 2 payments
|
2021: $20,770
| Mallinckrodt Hospital Products | None | $20,770 | 7 payments
|
2020: $32,103
| Mallinckrodt Hospital Products | None | $27,558 | 6 payments
|
| Intercept Pharmaceuticals | None | $4,545 | 4 payments
|
2019: $11,420
| Intercept Pharmaceuticals | None | $7,193 | 3 payments
|
| Mallinckrodt Enterprises | None | $3,698 | 5 payments
|
| Gilead Sciences | None | $450 | 2 payments
|
| Salix Pharmaceuticals a division of Bausch Health US | Xifaxan | $79 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| AstraZeneca Pharmaceuticals LP · A Two Part Phase Iia B Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Dose-Ranging Study To Assess Efficacy, Safety, and Tolerability of the Combination of Zibotentan and Dapagliflozin, and Dapagliflozin Monotherapy Versus Placebo in Participants With Cirrhosis With Features of Portal Hypertension · 2025 | Their institution | $91,047 |
| Mallinckrodt Enterprises LLC · A Multi-Center, Randomized, Placebo-Controlled, Double-Blind Study To Confirm Efficacy and Safety of Terlipressin in Subjects With Hepatorenal Syndrome Type 1 · 2019 | Their institution | $66,664 |
| Bausch Health US, LLC · A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (Ssd) for the Delay of Encephalopathy Decompensation in Cirrhosis · 2024 | Their institution | $47,894 |
| AstraZeneca Pharmaceuticals LP · A Two Part Phase Iia B Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Dose-Ranging Study To Assess Efficacy, Safety, and Tolerability of the Combination of Zibotentan and Dapagliflozin, and Dapagliflozin Monotherapy Versus Placebo in Participants With Cirrhosis With Features of Portal Hypertension · 2024 | Their institution | $42,868 |
| AstraZeneca Pharmaceuticals LP · A Two Part Phase Iia B Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Dose-Ranging Study To Assess Efficacy, Safety, and Tolerability of the Combination of Zibotentan and Dapagliflozin, and Dapagliflozin Monotherapy Versus Placebo in Participants With Cirrhosis With Features of Portal Hypertension · 2023 | Their institution | $19,200 |
| Bausch Health US, LLC · A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (Ssd) for the Delay of Encephalopathy Decompensation in Cirrhosis · 2025 | Their institution | $15,838 |
| Bausch Health US, LLC · A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (Ssd) for the Delay of Encephalopathy Decompensation in Cirrhosis · 2023 | Their institution | $3,500 |
Professional record
- NPI
- 1720009160
- Licence
- CA A71441California A71441: Current · expires 2028-04-30
- Trained
- New York Medical College, 1998
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Medicaid ID
- CA 00A714410
- Taxonomy
- Federal specialty code 207RG0100X (207RG0100X); Federal specialty code 204F00000X (204F00000X); Internal medicine (207R00000X); Federal specialty code 207RI0008X (207RI0008X); Federal specialty code 207RT0003X (207RT0003X)
- Mailing address
- 325 Distel Cir, Los Altos, CA, 94022
- NPI first listed
- 2006-07-21
- NPI last updated
- 2021-08-26
- NPI record certified
- 2020-12-04
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 1601 Esplanade Ste 3, Chico, CA, 95926 · 2367 Harrison Ave, Eureka, CA, 95501 · 1189 E Herndon Ave, Fresno, CA, 93720 · 1401 Spanos Ct Ste 125, Modesto, CA, 95355 · 101 Rowland Way Ste 220, Novato, CA, 94945 · 3300 Webster St Ste 202, Oakland, CA, 94609 · 795 El Camino Real, Palo Alto, CA, 94301 · 1315 Alhambra Blvd Ste 210, Sacramento, CA, 95816 · 1431 Noriega St, San Francisco, CA, 94122 · 2340 Clay St Fl 2, San Francisco, CA, 94115 · 3880 S Bascom Ave Ste 113, San Jose, CA, 95124 · 3883 Airway Dr, Santa Rosa, CA, 95403 · 990 Sonoma Ave, Santa Rosa, CA, 95404